Immunovant Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Eric Venker

İcra Kurulu Başkanı

US$55.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.6yrs
Yönetim Kurulu ortalama görev süresi	6.1yrs

Son yönetim güncellemeleri

Recent updates

Immunovant, Inc.'s (NASDAQ:IMVT) Intrinsic Value Is Potentially 97% Above Its Share Price

Feb 06

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

Dec 27

Immunovant: Switching Lead Candidates Increases Risk

Oct 14

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

Jun 27

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Apr 04

Immunovant: An Intriguing And Developing Story

Jan 25

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

CEO

Eric Venker (38 yo)

less than a year

Görev süresi

US$55,000

Tazminat

Dr. Eric Venker, M.D., Pharm D., has been Chief Executive Officer at Immunovant, Inc. since April 18, 2025 and serves as its Director since February 18, 2020. Dr. Venker served as Chief Operating Officer o...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Frank Torti	Executive Chairperson of the Board	6.1yrs	US$4.93m	0.0099% $ 518.3k
Eric Venker	CEO & Director	less than a year	US$55.00k	Veri yok
Melanie Gloria	Chief Operating Officer	1.2yrs	US$6.19m	0.0073% $ 384.9k
Christopher Van Tuyl	Chief Legal Officer & Corporate Secretary	1.1yrs	US$6.29m	0.0082% $ 432.2k
Tiago Girao	Chief Financial Officer	less than a year	Veri yok	Veri yok
Jay Stout	Chief Technology Officer	2.8yrs	US$4.04m	Veri yok
Christine Blodgett	Senior Vice President of Human Resources	no data	Veri yok	Veri yok
Andy Deig	Senior Vice President of Strategic Finance	no data	Veri yok	Veri yok
Julie Kirschling	Senior Vice President of Program & Alliance Management	no data	Veri yok	Veri yok
Jody Roth	Senior Vice President of Regulatory Affairs	no data	Veri yok	Veri yok
Becky Merlina	Senior VP & Global Head of Quality	2yrs	Veri yok	Veri yok
Yan Zheng	Senior Vice President of Biostatistics	2yrs	Veri yok	Veri yok

1.6yrs

Ortalama Görev Süresi

46.5yo

Ortalama Yaş

Deneyimli Yönetim: IMVT 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Frank Torti	Executive Chairperson of the Board	6.1yrs	US$4.93m	0.0099% $ 518.3k
Eric Venker	CEO & Director	5.9yrs	US$55.00k	Veri yok
Andrew Fromkin	Director	6.3yrs	US$530.04k	0.0015% $ 80.3k
Atul Pande	Independent Director	6.3yrs	US$517.54k	0.020% $ 1.0m
Jacob Bauer	Independent Director	less than a year	Veri yok	Veri yok
Douglas Hughes	Independent Director	6.1yrs	US$520.04k	0.0066% $ 345.0k
Robert Susman	Independent Director	less than a year	Veri yok	Veri yok

6.1yrs

Ortalama Görev Süresi

47yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IMVT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/01/04 17:10
Gün Sonu Hisse Fiyatı	2026/01/02 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2025/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Immunovant, Inc. 22 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Brian Skorney	Baird
Jason Matthew Gerberry	BofA Global Research
Louise Chen	Cantor Fitzgerald & Co.

Immunovant Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Medical Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$298k worth of stock

Immunovant, Inc. Announces Cessation of Michael Geffner, M.D., M.B.A. as Chief Medical Officer, Effective November 21, 2025

Immunovant, Inc., Annual General Meeting, Aug 27, 2025

Immunovant, Inc. Announces CEO Changes

CEO & Director recently sold US$365k worth of stock

Recent updates

Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement

Immunovant, Inc. has completed a Follow-on Equity Offering in the amount of $550.2 million.

Chief Medical Officer notifies of intention to sell stock

New minor risk - Insider selling

Chief Operating Officer recently sold US$298k worth of stock

Immunovant, Inc. Announces Cessation of Michael Geffner, M.D., M.B.A. as Chief Medical Officer, Effective November 21, 2025

Immunovant, Inc. to Report Q2, 2026 Results on Nov 10, 2025

Immunovant Unveils Durability and Treatment-Free Six-Month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Price target decreased by 7.9% to US$41.57

Immunovant, Inc., Annual General Meeting, Aug 27, 2025

Immunovant, Inc. Announces CEO Changes

CEO & Director recently sold US$365k worth of stock

Immunovant,Inc. Reports Topline Results from Its Phase 3 Study of Batoclimab in MG and Initial Results from Period 1 of Its Phase 2B Study in CIDP

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward

Now 27% undervalued after recent price drop

CEO & Director recently sold US$322k worth of stock

Immunovant, Inc.'s (NASDAQ:IMVT) Intrinsic Value Is Potentially 97% Above Its Share Price

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it has received $450 million in funding from Roivant Sciences Ltd., FMR LLC, Fidelity Management & Research Company LLC

Immunovant, Inc. announced that it expects to receive $450 million in funding from Roivant Sciences Ltd. and other investors

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

CEO & Director recently sold US$425k worth of stock

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

Immunovant: Switching Lead Candidates Increases Risk

Immunovant, Inc. Provides Update on Graves' Disease Development Program

CEO & Director recently sold US$480k worth of stock

Consensus EPS estimates fall by 17%

Immunovant, Inc., Annual General Meeting, Aug 12, 2024

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Immunovant: An Intriguing And Developing Story

Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults

CEO & Director recently sold US$532k worth of stock

Immunovant, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it expects to receive $169.999992 million in funding from Roivant Sciences Ltd.

Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Price target increased by 17% to US$34.42

CEO & Director recently sold US$1.3m worth of stock

Chief Financial Officer recently sold US$292k worth of stock

CEO & Director recently sold US$2.2m worth of stock

CEO & Director recently sold US$2.2m worth of stock

New minor risk - Insider selling

Immunovant, Inc., Annual General Meeting, Aug 21, 2023

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell Small Cap Comp Value Index

Price target increased by 14% to US$28.23

Chief Financial Officer recently sold US$52k worth of stock

Price target increased by 11% to US$20.25

Insider recently sold US$188k worth of stock

Chief Development & Technology Officer recently sold US$1.0m worth of stock

Price target increased to US$13.00

Less than half of directors are independent

Price target increased to US$11.00

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Chief Financial Officer recently sold US$118k worth of stock

Immunovant stock down on raising $75M though equity capital

Executive Chairperson of the Board recently bought US$116k worth of stock

Immunovant, Inc. Announces IMVT-1402

Immunovant Announces Two New Development Programs for Batoclimab

Immunovant, Inc., Annual General Meeting, Aug 17, 2022